Oculis Holding AG

OCSAW

Held by 1 specialist biotech fund

1 fund opened new positions. Next phase2 readout (OCS-01): Jun 2026.

Share

Signal Score

3.0/10

●●

See how each signal contributes— fund overlap, insider activity, catalyst timing, short interest (free trial)

1 specialist fund hold OCSAW with a Phase 2 in 48 days for OCS-01 (Uveitis Related Cystoid Macular Edema, Cystoid Macular Edema, Postoperative)

+1 more upcoming catalyst

Phase 2Q2 2026OCS-01Uveitis Related Cystoid Macular Edema, Cystoid Macular Edema, PostoperativeNCT05608837

Phase 3Q4 2026licaminlimabDry Eye Disease (DED)NCT07548632

Be first to know when this name moves

Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.

Start free trialfor share counts, dollar values & AI analysis

No insider purchases or sales detected in the past 90 days.

Verdad's Biotech White Paper, Part 1: Why Specialist Fund Holdings Predict Returns

6 min read

Verdad's Biotech White Paper, Part 2: Why Traditional Quant Factors Fail — and What Works Instead

6 min read

Fund Convergence: The Highest-Conviction Signal in Biotech Investing

5 min read

Track specialist biotech funds, insider signals, and AI analysis

Get free weekly alerts on fund moves and catalysts: